title: Association Between the Use of Proton Pump Inhibitors and the Risk of ESRD in Renal Diseases: A Population-Based, Case-Control Study.
abstract: Proton pump inhibitors (PPIs) use may be associated with nephritis and acute renal injury. The risk of PPIs and deterioration of renal function, in patients with renal diseases, needs to be investigated. A case-control study was conducted in a nation-wide data setting from the Taiwan National Health Insurance Research Database (NHIRD). This case-control study used data extracted from NHIRD between the years 2006 and 2011. We used propensity scores to match 3808 patients suffering from renal diseases (ICD-9-CM codes 580-589), with patients (aged ≥20 years) who had had a recent diagnosis of end-stage renal diseases (ESRDs) and had undertaken renal replacement therapy during the period of 2006 to 2011. The 3808 control subjects were selected from people who had a history of renal diseases, but no ESRD. The risk of ESRD in patients with renal diseases and PPIs use was estimated by using odds ratios (ORs) and 95% confidence intervals (CI). The use of a PPIs was associated with a significantly higher risk of ESRD (adjusted OR = 1.88, 95% CI = 1.71-2.06) in renal disease patients. Of all the types of PPI combined, the adjusted OR was 1.92 (95% CI = 1.74-2.13) for those on <100 cumulative DDD and was 1.74-fold (95% CI = 1.52-2.00) for those on ≥100 cumulative DDD. PPIs use is associated with the risk of ESRD in patients with renal diseases. It is necessary that appropriate prescription of PPIs coordinated with the close monitoring renal function of patients diagnosed with renal disease.
authors.affiliation: From the Division of Gastroenterology (Y-CP, H-ZY, C-SC), Department of Internal Medicine, Taichung Veterans General Hospital, Taichung; School of Medicine (Y-CP, H-ZY), National Yang-Ming University, Taipei; Management Office for Health Data (C-LL), China Medical University Hospital; College of Medicine (C-LL), China Medical University, Taichung; Department of Physiology (Y-LW), School of Medicine, National Yang-Ming University, Taipei; Graduate Institute of Clinical Medical Science and School of Medicine (C-HK), College of Medicine, China Medical University; and Department of Nuclear Medicine and PET Center(C-HK), China Medical University Hospital, Taichung, Taiwan.
authors.forename: Yen-Chun
authors.initials: YC
authors.lastname: Peng
authors.forename: Cheng-Li
authors.initials: CL
authors.lastname: Lin
authors.forename: Hong-Zen
authors.initials: HZ
authors.lastname: Yeh
authors.forename: Chi-Sen
authors.initials: CS
authors.lastname: Chang
authors.forename: Yu-Lin
authors.initials: YL
authors.lastname: Wu
authors.forename: Chia-Hung
authors.initials: CH
authors.lastname: Kao
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D018450:Disease Progression; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000453:epidemiology*; D007676:Kidney Failure, Chronic / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D057216:Propensity Score; D054328:Proton Pump Inhibitors / Q000008:administration & dosage*; D017582:Renal Replacement Therapy; D012307:Risk Factors; D013624:Taiwan
chemical_list: D054328:Proton Pump Inhibitors